X0202 SCHEDULE 13G/A 0001104659-25-112051 0001952142 XXXXXXXX LIVE 2 Common stock, par value $0.0001 per share 06/30/2026 0001840233 Xilio Therapeutics, Inc. 98422T209 828 Winter Street, Suite 300 Waltham MA 02451 Rule 13d-1(b) StemPoint Capital LP DE 0.00 628866.00 0.00 628866.00 628866.00 N 9.5 IA PN StemPoint Capital Management GP LLC DE 0.00 628866.00 0.00 628866.00 628866.00 N 9.5 OO StemPoint Capital Management GP LLC is a limited liability company. Michelle Ross X1 0.00 628866.00 0.00 628866.00 628866.00 N 9.5 HC IN Xilio Therapeutics, Inc. 828 Winter Street, Suite 300, Waltham, MA 02451 This filing is being jointly filed by StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross (collectively, the "Reporting Persons" and each a "Reporting Person"). The business addresses of each Reporting Person is: 520 Madison Avenue, 19th Floor New York, NY 10022 StemPoint Capital LP is a limited partnership organized under the laws of the State of Delaware. StemPoint Capital Management GP LLC is a limited liability company organized under the laws of the State of Delaware. Michelle Ross is a citizen of the United States of America. N IA HC Items 5-9 of each cover page are incorporated by reference. Each Reporting Person may be deemed to be the beneficial owner of 628,866 shares of Common Stock, par value $0.0001 per share (the "Common Stock"), consisting of (i) 343,154 shares of Common Stock through the exercise of a pre-funded warrant (the "Pre-Funded Warrants"), (ii) 142,856 shares of Common Stock underlying Series A Warrants, and (iii) 142,856 shares of Common Stock underlying Series C Warrants. The Pre-Funded Warrants, Series A Warrants, and Series C Warrants are subject to a beneficial ownership limitation of 9.99% (the "Beneficial Ownership Limitation"). Each Reporting Person may be deemed to beneficially own 9.5% shares of Common Stock, which is calculated based on (i) 5,982,839 shares of Common Stock reported as issued and outstanding as of May 8, 2026 in the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026, plus 343,154 shares of Common Stock which may be acquired upon the exercise of the Pre-Funded Warrants, 142,856 shares of Common Stock which may be acquired upon the exercise of Series A Warrants, and 142,856 shares of Common Stock which may be acquired upon the exercise of Series C Warrants, which are subject to the Beneficial Ownership Limitation, which amount has been added to the shares outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act. 628,866. Comment: Shared voting power includes 628,866 Warrants beneficially owned by the Reporting Persons. 628,866. Comment: Shared dispositive power includes 628,866 Warrants beneficially owned by the Reporting Persons. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) StemPoint Capital LP /s/ Sean C. Tan 08/14/2026 StemPoint Capital Management GP LLC /s/ Sean C. Tan 08/14/2026 Michelle Ross /s/ Michelle Ross 08/14/2026